ERK Suppression Attenuates Mitochondrial Fragmentation and Autophagy in SH-SY5Y Cells: Insights for Cerebral Ischemia-Reperfusion Injury

Study Background and Research Question

Cerebral ischemia-reperfusion injury (CIRI) is a primary cause of neurological disability and mortality following cardiac arrest or cardiopulmonary resuscitation. Despite advances in clinical support, the molecular mechanisms underlying neuronal damage during reperfusion remain incompletely resolved. Key cellular processes implicated include mitochondrial dynamics—specifically the balance of fission and fusion—and autophagy. Previous studies have highlighted the roles of extracellular signal-regulated kinase (ERK) activation, dynamin-related protein 1 (Drp1), and mitofusin 2 (Mfn2) in modulating these processes. However, the precise interplay between ERK signaling, mitochondrial fragmentation, and autophagy in the context of CIRI has not been fully elucidated (Yuan et al., 2023).

Key Innovation from the Reference Study

The study by Yuan et al. provides a mechanistic breakthrough by demonstrating that inhibition of ERK signaling reduces Drp1-mediated mitochondrial fragmentation and downregulates autophagy, thereby affording protection to SH-SY5Y neuroblastoma cells subjected to oxygen-glucose deprivation/reoxygenation (OGD/R)—a widely used in vitro model for CIRI. Notably, the work establishes a functional ERK–Drp1/Mfn2–autophagy axis, showing that pharmacological or genetic disruption of this pathway mitigates mitochondrial dysfunction and enhances cell survival. This mechanistic clarity positions ERK inhibition as a potential therapeutic strategy for CIRI (Yuan et al., 2023).

Methods and Experimental Design Insights

To dissect the signaling relationships, the authors pretreated SH-SY5Y cells with specific pharmacological agents 24 hours before subjecting them to OGD/R insult. The ERK pathway was manipulated using PD98059 (an ERK inhibitor) and TPA (an ERK activator). Autophagy was modulated with 3-Methyladenine (3-MA, a selective inhibitor of class III PI3K) and rapamycin (an autophagy activator). Drp1 and Mfn2 levels were altered using small interfering RNAs and recombinant plasmids, respectively. Mitochondrial morphology and autophagosome formation were assessed by transmission electron microscopy, while mitochondrial function was evaluated via mitochondrial permeability transition pore (mPTP) assays. Protein and mRNA levels of relevant markers were quantified using Western blotting and PCR. Cell viability and injury were evaluated through CCK8 and LDH release assays, respectively. Co-localization of p-ERK, p-Drp1, and LC3 was examined by multi-channel immunofluorescence (Yuan et al., 2023).

Core Findings and Why They Matter

The central findings are as follows:

• ERK inhibition enhances cell survival post-OGD/R: PD98059 pretreatment significantly improved viability and decreased injury in SH-SY5Y cells. In contrast, activating ERK with TPA exacerbated cell death (Yuan et al., 2023).
• Autophagy downregulation is neuroprotective: Similar to 3-MA, an established autophagy inhibitor, ERK inhibition led to decreased expression of autophagy markers (LC3-II, Beclin1) and increased levels of p62, indicating autophagic flux suppression. Rapamycin, conversely, intensified cell injury, highlighting the detrimental effects of excessive autophagy under these conditions.
• Mitochondrial fragmentation is mediated by Drp1/Mfn2 imbalance: OGD/R triggered Drp1 activation and loss of Mfn2, promoting mitochondrial fission. ERK inhibition, Drp1 knockdown, or Mfn2 overexpression each attenuated this fragmentation. The protective effect of ERK inhibition was compromised by overexpressing a phosphomimetic Drp1 mutant (S616E) or by Mfn2 knockdown, confirming the pivotal role of these proteins in the observed phenotype.
• ERK, Drp1, and LC3 co-localize in injured cells: Multiple immunofluorescence studies verified the spatial association between ERK activation, mitochondrial fission, and autophagy, supporting a model wherein these processes are tightly interconnected at the subcellular level.

Collectively, these results indicate that excessive autophagy—driven by ERK-dependent Drp1 activation and Mfn2 suppression—contributes to neuronal injury following ischemic insult. Suppressing this axis disrupts the pathological cascade and preserves mitochondrial integrity, underscoring the therapeutic potential of targeting autophagy and mitochondrial dynamics in CIRI (Yuan et al., 2023).

Comparison with Existing Internal Articles

Several internal resources contextualize and extend these findings. For instance, the article "3-Methyladenine: Precision Class III PI3K Inhibitor for Autophagy Research" details the utility of 3-MA in dissecting autophagy and cell migration pathways, particularly in cancer and neuroscience research. This aligns with Yuan et al.'s use of 3-MA as a pharmacological tool to validate the impact of autophagy inhibition on cell viability post-OGD/R (paper). Another resource, "3-Methyladenine (SKU A8353): Scenario-Based Solutions for Autophagy Assays", provides protocol-driven guidance for reliable autophagy inhibition, underpinning the reproducibility of such experiments across research domains. The reference study's mechanistic insights thereby both draw from and reinforce best practices discussed in these internal guides.

For broader context, the internal article "Bergeyella cardium Variant Induces Unique Macrophage Floatptosis" explores noncanonical cell death mechanisms in immune cells, highlighting the spectrum of regulated cell death pathways beyond classical apoptosis or autophagy. While the molecular drivers differ, both studies emphasize the translational importance of pathway-selective interventions in cell survival.

Limitations and Transferability

Although Yuan et al. provide compelling evidence in a neuronal cell line model, several limitations must be considered. SH-SY5Y cells, while valuable for mechanistic dissection, do not recapitulate the full cellular complexity or microenvironment of the mammalian brain. The pharmacological agents used (e.g., PD98059, 3-MA) may have off-target effects not accounted for in the present design. Furthermore, in vivo validation is necessary to confirm whether modulating the ERK–Drp1/Mfn2–autophagy axis will yield similar neuroprotective outcomes in whole-organism models of CIRI. Caution should also be exercised in extrapolating these results to other forms of neuronal injury or to non-neuronal cell types without further supporting data.

Protocol Parameters

• assay | 5–10 mM (3-MA) | autophagy inhibition in cell culture | Effective for transient inhibition of class III PI3K during OGD/R or similar stress models | product_spec
• incubation time | ~10 hours | cell injury/survival assays post-stress | Balances inhibition efficacy and cell viability | product_spec
• solvent | ≥7.45 mg/mL in DMSO | stock preparation | Ensures solution stability prior to dilution in culture medium | product_spec
• storage | -20°C (solid); DMSO stocks below -20°C | long-term use | Maintains compound potency and reproducibility | product_spec
• assay | PD98059 10–50 μM | ERK inhibition | Literature precedent for kinase inhibition in neuronal models | workflow_recommendation

Research Support Resources

To replicate or extend autophagy-related experiments as described by Yuan et al., researchers may utilize 3-Methyladenine (SKU A8353), a selective inhibitor of class III PI3K (Vps34), suitable for transient or sustained autophagy modulation across diverse cell models. Detailed preparation, storage, and workflow recommendations are available through APExBIO’s resource pages. For protocol troubleshooting and experimental design guidance, consult scenario-driven internal articles to ensure reproducibility and optimal inhibitor application (internal article).